Market Snapshot
| Study Period: | 2018 - 2026 |
| Base Year: | 2020 |
| Fastest Growing Market: | Asia Pacific |
| Largest Market: | North America |
| CAGR: | >12.5 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
Market Overview
The major factors attributing to the growth of the viral inactivation market are a rise in the global prevalence of chronic diseases like cancer, autoimmune disorders, and other diseases along with an increase in healthcare expenditure. For instance, in 2019, the American Cancer Society has reported that there would be 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the United States which is expected to increase in the forecast period. Thus, due demand for the development of novel therapies is expected to drive the market during the forecast period.
Scope of the Report
As per the scope of the report, Viral inactivation is a method of viral processing, where the final product may contain the viruses in an inactive form. The Virus inactivation process is a critical step in process development for biologicals such as tissue and tissue products, stem cell products, and vaccines, and therapeutics.
| By Method | |
| Solvent Detergent Method | |
| pH Adjustment Method | |
| Pasteurization | |
| Others |
| By Product | |
| Viral Inactivation Systems and Accessories | |
| Kits and Reagents | |
| Others |
| By Application | |
| Vaccines and Therapeutics | |
| Blood & Blood Products | |
| Cellular & Gene Therapy Products | |
| Others |
| By End User | |
| Pharmaceutical and Biotechnology Companies | |
| Contract Research Organisations | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Key Market Trends
Vaccines and Therapeutics Segment is Expected to Hold the Largest Market Share in the Viral Inactivation Market
Vaccines and Therapeutics segment is anticipated to hold the largest market share in the global viral inactivation market. The highest market revenue is due to higher incidences and huge economic burden of chronic diseases such as Cancer, that demanded the inactivated vaccines along with increasing government support for pharmaceutical and biotechnology industries to invest in R&D of novel therapeutics.
Also, the process of viral inactivation has been made mandatory step by regulatory authorities, such as the US Food and Drug Association (FDA) for investigational new drug (IND) submission in the view of safety concerns which contributes to the growth of the global viral inactivation market.
To understand key trends, Download Sample Report
North America Dominates the Market and Expected to do Same in the Forecast Period.
North America is expected to dominate the overall, throughout the forecast period. In North America, the United States holds the largest market share in terms of revenue. Also, advanced healthcare infrastructure, the presence of major pharmaceutical and biopharmaceutical companies, and significant healthcare R&D expenditure by government and companies in the United States are the key factors estimated to fuel the market in North America.
Followed by North America, Europe accounts for the second-highest market share in the global viral inactivation market owing to the rapid R&D investments in the life sciences industry and new product launches in the region.
The Asia Pacific is set to grow at the fastest rate during the forecast period, driven by the developing healthcare infrastructure in emerging nations and rising awareness programs. Also, the ongoing trials in the region and rise in the prevalence of chronic diseases in emerging economies such as India and China will further stimulate the viral inactivation market growth in the region over the forecast period.
To understand geography trends, Download Sample Report
Competitive Landscape
The viral inactivation market is moderately consolidated, competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market with various development strategies. Some prominent players are making acquisitions and effective mergers to consolidate their market positions across the globe. Furthermore, new entrants are expected to enter the market with innovative product pipeline and continuous technological innovations that increase the market revenue over the forecast period.
Major Players
Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Rapid Growth in Pharmaceutical and Biotechnology Industries and Strong R&D Investments
-
4.2.2 Increasing Number of New Drug Launches with Increased Government Support
-
-
4.3 Market Restraints
-
4.3.1 Highly Expensive Manufacturing Processes of Biosimilars
-
4.3.2 Complex Regulatory Framework for Validation of Inactivated Products
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Method
-
5.1.1 Solvent Detergent Method
-
5.1.2 pH Adjustment Method
-
5.1.3 Pasteurization
-
5.1.4 Others
-
-
5.2 By Product
-
5.2.1 Viral Inactivation Systems and Accessories
-
5.2.2 Kits and Reagents
-
5.2.3 Others
-
-
5.3 By Application
-
5.3.1 Vaccines and Therapeutics
-
5.3.2 Blood & Blood Products
-
5.3.3 Cellular & Gene Therapy Products
-
5.3.4 Others
-
-
5.4 By End User
-
5.4.1 Pharmaceutical and Biotechnology Companies
-
5.4.2 Contract Research Organisations
-
5.4.3 Others
-
-
5.5 Geography
-
5.5.1 North America
-
5.5.1.1 United States
-
5.5.1.2 Canada
-
5.5.1.3 Mexico
-
-
5.5.2 Europe
-
5.5.2.1 Germany
-
5.5.2.2 United Kingdom
-
5.5.2.3 France
-
5.5.2.4 Italy
-
5.5.2.5 Spain
-
5.5.2.6 Rest of Europe
-
-
5.5.3 Asia-Pacific
-
5.5.3.1 China
-
5.5.3.2 Japan
-
5.5.3.3 India
-
5.5.3.4 Australia
-
5.5.3.5 South Korea
-
5.5.3.6 Rest of Asia-Pacific
-
-
5.5.4 Middle-East and Africa
-
5.5.4.1 GCC
-
5.5.4.2 South Africa
-
5.5.4.3 Rest of Middle-East and Africa
-
-
5.5.5 South America
-
5.5.5.1 Brazil
-
5.5.5.2 Argentina
-
5.5.5.3 Rest of South America
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Merck KGaA
-
6.1.2 Cytiva (Taleo)
-
6.1.3 Sartorius AG
-
6.1.4 Texcell SA
-
6.1.5 Parker Hannifin Corp
-
6.1.6 Vironova AB
-
6.1.7 Viral Inactivated Plasma Systems SA
-
6.1.8 Rad Source Technologies Inc
-
6.1.9 Charles River Laboratories, Inc.
-
6.1.10 WuXi PharmaTech
-
*List Not Exhaustive -
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Viral Inactivation Market market is studied from 2018 - 2026.
What is the growth rate of Viral Inactivation Market?
The Viral Inactivation Market is growing at a CAGR of >12.5% over the next 5 years.
Which region has highest growth rate in Viral Inactivation Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Viral Inactivation Market?
North America holds highest share in 2020.
Who are the key players in Viral Inactivation Market?
Merck KGaA, Parker Hannifin Corp, Sartorius AG, Texcell SA, Cytiva (Taleo) are the major companies operating in Viral Inactivation Market.
